Table 1.
Predominant clinical characteristics and laboratory findings in patients from non-severe and severe group.
| Characteristics | All patients (n = 175) | Non-severe group (n = 132) | Severe group (n = 43) | p -value |
|---|---|---|---|---|
| Age | 44.79 ± 13.65 | 42.89 ± 13.27 | 50.63 ± 13.29 | 0.001 |
| Gender, male/female | 102/73 | 73/59 | 29/14 | 0.221 |
| Course | ||||
| Admission duration**, median (1/4–3/4 quantile), day | 19 (16–26) | 18.00 (15–23) | 23.50 (20–30) | <0.001 |
| ICU duration, median (1/4–3/4 quantile), day | 9.50 (6–15) | / | 9.50 (6–15) | / |
| Course***, median (1/4–3/4 quantile), day | 25 (20–31) | 24 (19–29) | 31 (27–35) | <0.001 |
| Symptom | ||||
| Fever | 148 (84.6%) | 111 (84.1%) | 37 (86.1%) | 0.948 |
| Cough | 94 (53.7%) | 68 (51.5%) | 26 (60.5%) | 0.340 |
| Chest tightness | 24 (13.7%) | 13 (9.8%) | 11 (25.6%) | 0.019 |
| Fatigue | 25 (14.3%) | 17 (12.9%) | 8 (18.6%) | 0.496 |
| Diarrhea | 5 (2.9%) | 5 (3.8%) | 0 (0%) | 0.336* |
| Headache | 5 (2.9%) | 5 (3.8%) | 0 (0%) | 0.336* |
| Others | 1 (2.0%) | 1 (0.8%) | 0 (0%) | 1.000* |
| Underlying comorbidity | ||||
| Yes/no | 48/127 | 30/102 | 18/25 | 0.025 |
| Endocrine system disease | 23 (13.1%) | 13 (9.9%) | 10 (23.3%) | 0.045 |
| Digestive system disease | 10 (5.7%) | 8 (6.1%) | 2 (4.7%) | 1.000 |
| Cardiovascular and cerebrovascular disease | 11 (6.3%) | 5 (3.8%) | 6 (14.0%) | 0.028* |
| Malignancy | 3 (1.7%) | 1 (0.8%) | 2 (4.7%) | 0.150* |
| Mental disease | 2 (1.1%) | 1 (0.8%) | 1 (2.3%) | 0.432* |
| Respiratory system disease | 2 (1.1%) | 1 (0.8%) | 1 (2.3%) | 0.432* |
| Other | 5 (2.9%) | 4 (3.0%) | 1 (2.3%) | 1.000* |
| Laboratory test | ||||
| White blood cell count, mean ± sd, × 109/L | 5.53 ± 2.33 | 5.32 ± 1.96 | 6.35 ± 3.29 | 0.274 |
| Lymphocyte count, mean ± sd, × 109/L | 1.09 ± 0.44 | 1.19 ± 0.43 | 0.80 ± 0.35 | <0.001 |
| Lactate dehydrogenase, mean ± sd, U/L | 260.43 ± 95.46 | 242.80 ± 65.69 | 341.39 ± 154.50 | <0.001* |
| C-reactive protein, mean ± sd, mg/L | 28.37 ± 35.67 | 21.18 ± 26.76 | 50.28 ± 48.70 | <0.001* |
| Procalcitonin, median (range), ng/mL | 0.09 ± 0.38 | 0.10 ± 0.42 | 0.06 ± 0.05 | 0.339* |
| Alanine aminotransferase, mean ± sd, U/L | 39.50 ± 44.99 | 38.60 ± 47.59 | 42.55 ± 35.20 | 0.078* |
| Aspartate aminotransferase, mean ± sd, U/L | 32.76 ± 30.07 | 31.99 ± 32.95 | 35.30 ± 17.52 | 0.008* |
| Therapeutic strategy | ||||
| Antiviral therapy | 169 (96.6%) | 127 (96.2%) | 42 (97.7%) | 1.000* |
| Oxygen inhalation | 121 (69.1%) | 78 (59.1%) | 43 (100.0%) | <0.001* |
| Antibiotic treatment | 81 (46.3%) | 51 (38.6%) | 30 (69.8%) | <0.001 |
| Interferon therapy | 44 (25.1%) | 37 (28.0%) | 7 (16.3%) | 0.182 |
| Glucocorticoid therapy | 7 (4.0%) | 4 (3.0%) | 3 (7.0%) | 0.001 |
*
Wilcoxon's rank-sum test and Fisher's exact test were used if non-normal distribution or heterogenous variance of the data was detected.
**
Admission duration was calculated from the 1st day of hospitalization to the day of discharge.
***
Course was calculated from the day of onset to the day of discharge.
The p value in bold indicates that P is less than 0.05 and is statistically significant.